Posted by Michael Wonder on 12 Sep 2023
NICE issues two recommendations for UCB's inflammatory disease drug
11 September 2023 - NICE has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now authorised by the institute to treat adults with psoriatic arthritis and axial spondyloarthritis.
Bimzelx, which is already authorised in the UK to treat certain patients with plaque psoriasis, is now the first treatment available for psoriatic arthritis and axial spondyloarthritis that is designed to inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory disease.
